DBV Technologies (NASDAQ:DBVT) Given “Market Outperform” Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Thursday morning,Benzinga reports. JMP Securities currently has a $21.00 target price on the stock.

DBVT has been the topic of a number of other reports. The Goldman Sachs Group raised shares of DBV Technologies to a “sell” rating and set a $7.25 price target on the stock in a research note on Thursday, May 29th. HC Wainwright boosted their target price on DBV Technologies from $7.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, May 5th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, May 9th. Finally, Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $14.75.

DBV Technologies Price Performance

Shares of DBVT opened at $9.21 on Thursday. The business’s 50-day moving average is $9.22 and its 200-day moving average is $6.24. The company has a market capitalization of $252.26 million, a price-to-earnings ratio of -1.87 and a beta of -0.63. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $12.78.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Friday, April 11th. The company reported ($1.10) EPS for the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative return on equity of 278.24%. The company had revenue of $0.51 million for the quarter. Equities research analysts expect that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.